Devicemaker targets athletes with concussion-detecting tech; Small-time device firms face tough path;

@FierceMedDev: While purchasers praise the FDA's device ID plan, members of the industry remain wary. Item | Follow @FierceMedDev

 @MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

 @DamianFierce: Roche gets its second FDA diagnostic approval this week, this time for a virus test. Story | Follow @DamianFierce

> Devicemaker Cenora is developing a mobile medical device designed to detect concussions, hoping to get 510(k) clearance and use the tech on athletes. News

> Crain's takes a look at the rocky road small devicemakers face when trying to get their techs on the market. Article

> Vascular Flow Technologies is touting positive first-in-man trial results for Spiral Flow, an investigative bypass graft designed to treat peripheral artery disease. Release

> The U.K.'s Deltex Medical has seen a sales boost for its CardioQ surgical probe, thanks to a NICE recommendation and demand from the National Health Service. Story

Biotech News

 @FierceBiotech: Pfizer inks licensing deal with Russia's SatRx for diabetes drug. Release | Follow @FierceBiotech

 @JohnCFierce: So K-V says that if the FDA doesn't ride to its rescue on Makena comp, it's going bankrupt in a few months. Buh-bye. More | Follow @JohnCFierce

 @RyanMFierce: Interesting biotech startup opportunity: nanoparticles that reduce amount of active drug needed combat clots. More | Follow @RyanMFierce

> Forest Labs pressured to pull trigger on M&A after patent expires on Lexapro. Story

> Struggling K-V Pharma brings lawsuit against FDA. More

> Biotech startup ADCT and U.K. researchers conspire to arm anti-cancer 'warheads'. News

Pharma News

 @FiercePharma: Top EMA lawyer jumps ship for SIdley Austin, private firm repping pharma companies. Agency investigates--FT. More | Follow @FiercePharma

> Pfizer trimming health claims on Centrum. Story

> NICE turns down Avastin for breast cancer. News

> K-V says it will go bankrupt without FDA intervention. Article